Coleman R - Search Results

1

Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval.

Cadieux B, Coleman R, Jafarinasabian P, Lipton A, Orlowski RZ, Saad F, Scagliotti GV, Shimizu K, Stopeck A. Cadieux B, et al. Among authors: coleman r. J Bone Oncol. 2022 Feb 7;33:100416. doi: 10.1016/j.jbo.2022.100416. eCollection 2022 Apr. J Bone Oncol. 2022. PMID: 35242510 Free PMC article. Review.

2

Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer.

Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F, Smith MR. Cook RJ, et al. Among authors: coleman r. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3361-7. doi: 10.1158/1078-0432.CCR-06-0269. Clin Cancer Res. 2006. PMID: 16740758 Clinical Trial.

3

Pathologic fractures correlate with reduced survival in patients with malignant bone disease.

Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Saad F, et al. Among authors: coleman r. Cancer. 2007 Oct 15;110(8):1860-7. doi: 10.1002/cncr.22991. Cancer. 2007. PMID: 17763372 Free article. Clinical Trial.

4

Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.

Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS, Coleman R, Paterson AH, Peterson MC, Fan M, Kinsey A, Jun S. Lipton A, et al. Among authors: coleman r. J Clin Oncol. 2007 Oct 1;25(28):4431-7. doi: 10.1200/JCO.2007.11.8604. Epub 2007 Sep 4. J Clin Oncol. 2007. PMID: 17785705 Clinical Trial.

5

Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer.

Smith MR, Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F. Smith MR, et al. Among authors: coleman r. Urology. 2007 Aug;70(2):315-9. doi: 10.1016/j.urology.2007.03.071. Urology. 2007. PMID: 17826496 Free PMC article. Clinical Trial.

6

Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions.

Coleman R, Brown J, Terpos E, Lipton A, Smith MR, Cook R, Major P. Coleman R, et al. Cancer Treat Rev. 2008 Nov;34(7):629-39. doi: 10.1016/j.ctrv.2008.05.001. Epub 2008 Jun 24. Cancer Treat Rev. 2008. PMID: 18579314 Free PMC article. Review.

7

Dosing of zoledronic acid throughout the treatment continuum in breast cancer.

Hadji P, Gnant M, Aapro M, Lipton A, Coleman R. Hadji P, et al. Among authors: coleman r. Crit Rev Oncol Hematol. 2011 Aug;79(2):175-88. doi: 10.1016/j.critrevonc.2010.07.017. Epub 2010 Sep 16. Crit Rev Oncol Hematol. 2011. PMID: 20846875 Review.

8

Zoledronic acid use in cancer patients: more than just supportive care?

Coleman R, Cook R, Hirsh V, Major P, Lipton A. Coleman R, et al. Cancer. 2011 Jan 1;117(1):11-23. doi: 10.1002/cncr.25529. Cancer. 2011. PMID: 21235033 Free article. Review.

9

Consensus on the utility of bone markers in the malignant bone disease setting.

Coleman R, Costa L, Saad F, Cook R, Hadji P, Terpos E, Garnero P, Brown J, Body JJ, Smith M, Lee KA, Major P, Dimopoulos M, Lipton A. Coleman R, et al. Crit Rev Oncol Hematol. 2011 Dec;80(3):411-32. doi: 10.1016/j.critrevonc.2011.02.005. Epub 2011 Mar 15. Crit Rev Oncol Hematol. 2011. PMID: 21411334 Review.

10

Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.

Gartrell BA, Coleman R, Efstathiou E, Fizazi K, Logothetis CJ, Smith MR, Sonpavde G, Sartor O, Saad F. Gartrell BA, et al. Among authors: coleman r. Eur Urol. 2015 Nov;68(5):850-8. doi: 10.1016/j.eururo.2015.06.039. Epub 2015 Jul 4. Eur Urol. 2015. PMID: 26153564 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,468 results

Search Page